XERS · Xeris Biopharma Holdings, Inc. · Metrics
$10.13
+1.05 (+11.56%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$1.66B
Shares
182.32M
Volume · Oct 5
4.66M
Avg daily vol (3M)
2.2M
XERS metrics
65 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$10.13
Market cap
$1.66B
Price action
20 metricsPrice change (1W)
-0.2%
Price change (30D)
+7.1%
Price change (3M)
+9.7%
Price change (6M)
+50.3%
Price change (YTD)
+15.7%
Price change (1Y)
+9.3%
Trailing year
Price change (5Y)
+267.6%
52-week high
$9.98
52-week low
$5.29
Change from 52-week high
-9.0%
Change from 52-week low
+71.6%
Annualized volatility
53.3%
Annualized volatility (3M)
51.8%
Beta
0.8
RSI (14D)
55.9
Price vs SMA 50
+7.4%
Price vs SMA 200
+26.2%
Avg volume (3M)
2.17M
Relative volume
0.8
Average dollar volume
$18.83M
Company
3 metricsSector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
182.32M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
4.9×
reciprocal yield 20.2%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
29.3
reciprocal yield 3.4%
Earnings yield
-1.0%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
3.7×
reciprocal yield 26.9%
EV / revenue historical average (5Y)
3.6×
reciprocal yield 28.0%
EV / EBIT historical average (3Y)
66.2×
reciprocal yield 1.5%
EV / EBIT historical average (5Y)
66.2×
reciprocal yield 1.5%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-06
Profitability
9 metricsGross margin
—
Operating margin
10.9%
Trailing 12 months
Net margin
-5.1%
Gross profit (TTM)
—
Operating profit (TTM)
$36.59M
Net income (TTM)
−$17.16M
Trailing 12 months
Diluted EPS (TTM)
$-0.10
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+28.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$335.41M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+8.4%
Year over year · more shares
Revenue CAGR (3Y)
+38.3%
Revenue CAGR (5Y)
+70.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-4.2%
Debt / equity
—
Current ratio
1.4
EBITDA (TTM)
$37.93M
Free cash flow (TTM)
—
Quick ratio
1.0
Interest coverage
1.3
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$121.75M
Total assets
$411.90M
Total debt
$252.59M
Cash flow & spend
7 metricsOperating cash flow (TTM)
$56.61M
Capital expenditures (TTM)
—
R&D (TTM)
$34.81M
SG&A (TTM)
$208.14M
Stock compensation (TTM)
$28.12M
R&D / revenue
10.4%
Stock compensation / revenue
8.4%
Ownership (13F)
3 metrics13F filers
241
13F filer change QoQ
+4
Institutional ownership
60.2%
Short interest
3 metricsShort interest
4.4%
Latest settlement · 4.8 days to cover
Days to cover
4.8d
Short-squeeze score
71 / 100
Insider activity
2 metricsNet insider buying (90D)
−$1.20M
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—